Extension of Requirement for Biometric Passport Issuance.

Written by John Rians

The requirement for Visa Waiver travelers to have biometrics included in their passports has been extended for one year, to October 26, 2005. All newly issued passports must be biometrically enabled by this time. The extension was necessary to avoid potential disruption of international travel and to allow for adequate time to develop programs for producing a more secure, biometrically enabled passport by those countries enrolled in Visa Waiver programs.

Because of security concerns related to this extension,repparttar Department of Homeland Security will begin enrolling Visa Waiver Program travelers throughrepparttar 119265 US-VISIT program (U.S. Visitor and Immigrant Status Indicator Technology) at all airports and seaports on September 30, 2004. Enrollment in US-VISIT allowsrepparttar 119266 United States to continue its international efforts to enhance border security, while facilitating legitimate travel. The US-VISIT system requires two digital index finger scans, and a digital photograph ofrepparttar 119267 traveler to verify his or her identity.

The second requirement for Visa Waiver Program travelers will come into effect on October 26, 2004. From that date on, all passports used for travel inrepparttar 119268 Visa Waiver Program must be machine-readable. Last year,repparttar 119269 Secretary of State granted a postponement until October 26, 2004, making thisrepparttar 119270 new date by which Visa Waiver Program travelers from 21 countries must present a machine-readable passport to be admitted torepparttar 119271 United States without a visa.

Should You Hire a Vioxx Lawyer?

Written by Michael Monheit, Esquire

If you or a beloved family member has suffered a Vioxx related heart attack, other cardiovascular problems, or a Vioxx induced stroke then you may be eligible to be part of a Vioxx class action suit or individual Vioxx litigation case.

The grounds for filing a Vioxx stroke, heart attack, or sudden death litigation case are based on releasing and marketing Vioxx as a safe alternative for chronic pain. Vioxx and other NSAID (non-steroidal, anti-inflammatory drugs) were not tested long-term to determine its patient safety factor. A few years passed beforerepparttar FDA advised Merck to properly post warnings onrepparttar 119264 label. During that time-frame, thousands of doctors prescribed Vioxx to thousands of patients impervious torepparttar 119265 imminent health threat that lay ahead.

How much does a Vioxx lawsuit cost? --------- Most Vioxx law firms will accept clients on a contingency fee basis. There is no fee, unless and until there is a recovery. If nothing is recovered during your Vioxx lawsuit thenrepparttar 119266 client pays nothing. The contingent fee is based on a pre-agreed percentage ofrepparttar 119267 recovery depending onrepparttar 119268 complexity and risks involved in your Vioxx case.

What’srepparttar 119269 difference between a Vioxx class action suit, individual litigation, and MDL (multi district litigation)? --------- In a Vioxx class action suit, individuals who have similar cases would be "joined together" in a "class" to prosecute their claims in a "more efficient" manner. This process begins when one person (or more) agrees to serve asrepparttar 119270 class representative. This "class rep" is then subject to approval byrepparttar 119271 court. There are a series of requirements thatrepparttar 119272 court reviews -- but most significantly, whetherrepparttar 119273 claims ofrepparttar 119274 "class rep" are typical ofrepparttar 119275 claims of other members ofrepparttar 119276 proposed class. The class representative is proceeding not only on his or her own behalf, but also on behalf of all others who are similarly situated. In this case, there is only ONE lawsuit,repparttar 119277 result of which binds all class members. In order to determine ifrepparttar 119278 class will receive fair and adequate representation,repparttar 119279 court will generally consider whetherrepparttar 119280 attorney forrepparttar 119281 class has experience in handling class actions and/or claims similar to those ofrepparttar 119282 proposed class. In addition,repparttar 119283 court will determine whether there are any conflicts inrepparttar 119284 interests ofrepparttar 119285 class members.

In individual Vioxx litigation, each person's lawyer prosecutes their case, apart from any other cases. If a lawyer has multiple clients, each client would receive individual attention and would have their own Vioxx lawsuit.

Even with individual Vioxx litigation, some cases end up in Federal court, due to a diversity of citizenship betweenrepparttar 119286 claimant and Merck. In these cases,repparttar 119287 individual claim gets temporarily consolidated with other cases in Federal court. But this consolidation is ONLY forrepparttar 119288 purposes of discovery, and does not impactrepparttar 119289 right to an individual trial for that person's Vioxx lawsuit. The MDL gives each personrepparttar 119290 benefit through judicial economy and efficiencies of scale. For example, if Merck is also being sued by 10,000 other Vioxx plaintiffs acrossrepparttar 119291 country, just taking depositions in allrepparttar 119292 various jurisdictions could delayrepparttar 119293 trial date by years. But when all those individual Vioxx lawsuits are consolidated for discovery, it helps to save time and money forrepparttar 119294 Vioxx clients. In addition, it placesrepparttar 119295 Vioxx plaintiffs on a more level playing field.

Cont'd on page 2 ==>
ImproveHomeLife.com © 2005
Terms of Use